Epichaperome inhibition targets TP53- mutant AML and AML stem/progenitor cells
Blood · 2023
DOI: 10.1182/blood.2022019047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, 2023. Verfasst von Bing Z Carter und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Antineoplastic Agents, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
TP 53-mutant acute myeloid leukemia (AML) remains the ultimate therapeutic challenge. Epichaperomes, formed in malignant cells, consist of heat shock protein 90 (HSP90) and associated proteins that support the maturation, activity, and stability of oncogenic kinases and transcription factors including mutant p53. High-throughput drug screening identified HSP90 inhibitors as top hits in isogenic TP53–wild-type (WT) and -mutant AML cells. We detected epichaperomes in AML cells and stem/progenitor cells with TP53 mutations but not in healthy bone marrow (BM) cells. Hence, we investigated the therapeutic potential of specifically targeting epichaperomes with PU-H71 in TP53-mutant AML based on its preferred binding to HSP90 within epichaperomes. PU-H71 effectively suppressed cell intrinsic stress responses and killed AML cells, primarily by inducing apoptosis; targeted TP53-mutant stem/progenitor cells; and prolonged survival of TP53-mutant AML xenograft and patient-derived xenograft models, but it had minimal effects on healthy human BM CD34+ cells or on murine hematopoiesis. PU-H71 decreased MCL-1 and multiple signal proteins, increased proapoptotic Bcl-2-like protein 11 levels, and synergized with BCL-2 inhibitor venetoclax in TP53-mutant AML. Notably, PU-H71 effectively killed TP53-WT and -mutant cells in isogenic TP53-WT/TP53-R248W Molm13 cell mixtures, whereas MDM2 or BCL-2 inhibition only reduced TP53-WT but favored the outgrowth of TP53-mutant cells. Venetoclax enhanced the killing of both TP53-WT and -mutant cells by PU-H71 in a xenograft model. Our data suggest that epichaperome function is essential for TP53-mutant AML growth and survival and that its inhibition targets mutant AML and stem/progenitor cells, enhances venetoclax activity, and prevents the outgrowth of venetoclax-resistant TP53-mutant AML clones. These concepts warrant clinical evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Center for Infectious and Inflammatory Disease, Texas A&M University, Institute of Bioscience and Technology, Houston, TX.
- Center for Translational Cancer Research, Texas A&M University, Institute of Bioscience and Technology, Houston, TX.
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
ORCID-Profile: Bing Z Carter, Andrea D Bedoy, Lauren B Ostermann, Clifford Stephan, Naveen Pemmaraju, Steffen Boettcher, Benjamin L Ebert, Georgios I Karras, Michael Andreeff
Förderung
- NCI NIH HHS
Zitieren
APA
Carter, B. Z., Mak, P. Y., Muftuoglu, M., Tao, W., Ke, B., Pei, J., Bedoy, A. D., Ostermann, L. B., Nishida, Y., Isgandarova, S., Sobieski, M., Nguyen, N., Powell, R. T., Martinez-Moczygemba, M., Stephan, C., Basyal, M., Pemmaraju, N., Boettcher, S., Ebert, B. L., …, & Andreeff, M. (2023). Epichaperome inhibition targets TP53- mutant AML and AML stem/progenitor cells. Blood. https://doi.org/10.1182/blood.2022019047
Vancouver
Carter BZ, Mak PY, Muftuoglu M, Tao W, Ke B, Pei J, et al. Epichaperome inhibition targets TP53- mutant AML and AML stem/progenitor cells. Blood. 2023. doi:10.1182/blood.2022019047
BibTeX
@article{Carter2023,
author = {Carter, Bing Z and Mak, Po Yee and Muftuoglu, Muharrem and Tao, Wenjing and Ke, Baozhen and Pei, Jingqi and Bedoy, Andrea D and Ostermann, Lauren B and Nishida, Yuki and Isgandarova, Sevinj and Sobieski, Mary and Nguyen, Nghi and Powell, Reid T and Martinez-Moczygemba, Margarita and Stephan, Clifford and Basyal, Mahesh and Pemmaraju, Naveen and Boettcher, Steffen and Ebert, Benjamin L and Shpall, Elizabeth J and Wallner, Barbara and Morgan, Robert A and Karras, Georgios I and Moll, Ute M and Andreeff, Michael},
title = {Epichaperome inhibition targets TP53- mutant AML and AML stem/progenitor cells},
journal = {Blood},
year = {2023},
doi = {10.1182/blood.2022019047}
}
EUVIMED